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A B S T R A C T
After decades of research, the molecular neuropathology of Alzheimer’s disease (AD) is still one of the hot topics
in biomedical sciences. Some studies suggest that soluble amyloid β (Aβ) oligomers act as causative agents in the
development of AD and could be initiators of its complex neurodegenerative cascade. On the other hand, there is
also evidence pointing to Aβ oligomers as mere aggravators, with an arguable role in the origin of the disease.
In this line of research, the relative contribution of soluble Aβ oligomers to neuronal damage associated with
metabolic disorders such as Type 2 Diabetes Mellitus (T2DM) and obesity is being actively investigated. Some
authors have proposed the endoplasmic reticulum (ER) stress and the induction of the unfolded protein response
(UPR) as important mechanisms leading to an increase in Aβ production and the activation of neuroin-
flammatory processes. Following this line of thought, these mechanisms could also cause cognitive impairment.
The present review summarizes the current understanding on the neuropathological role of Aβ associated
with metabolic alterations induced by an obesogenic high fat diet (HFD) intake. It is believed that the combi-
nation of these two elements has a synergic effect, leading to the impairement of ER and mitochondrial func-
tions, glial reactivity status alteration and inhibition of insulin receptor (IR) signalling. All these metabolic
alterations would favour neuronal malfunction and, eventually, neuronal death by apoptosis, hence causing
cognitive impairment and laying the foundations for late-onset AD (LOAD).
Moreover, since drugs enhancing the activation of cerebral insulin pathway can constitute a suitable strategy
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for the prevention of AD, we also discuss the scope of therapeutic approaches such as intranasal administration
of insulin in clinical trials with AD patients.
1. Introduction
The study of Alzheimer’s disease (AD) began in the early twentieth
century, when the German physician Alois Alzheimer described the first
case of this pathology in a 51-year old woman called Auguste Deter [1].
Her symptoms included remarkable memory loss, language difficulties
and personality changes. After the post-mortem examination, the brain
autopsy revealed specific neuropathological changes in the cerebral
cortex [1–4], now known as the classical morphological symptoms of
AD: amyloid β (Aβ) peptide plaques derived of the activity of the
amyloidogenic pathway and neurofibrillary tangles (NFTs), composed
by hyperphosphorylated tau protein [3–8].
At present, the aetiological hypothesis most supported by the sci-
entific community is the “amyloid cascade hypothesis”, which is sum-
marized in Fig. 1. According to this hypothesis, under physiological
conditions amyloid β protein percussor (AβPP) is cleaved by the en-
zyme α-secretase, following the non-amyloidogenic pathway. This
precludes formation of amyloidogenic peptides and leads to a release of
secreted AβPP alpha (sAβPPα), which has neuroprotective properties
[5]. On the contrary, in the amyloidogenic pathway, AβPP is cleaved by
β-secretase (BACE-1) at N-terminus and, in turn, γ/ε-secretase cleaves it
at the C-terminus to yield secreted AβPP (sAβPP), Aβ40/42 fragments
(which remain in the extracellular space) and a C-terminal fragment
with 99 amino acids (C99) that can be translocated to the nucleus.
Here, it may induce expression of genes that promote neuronal death by
apoptosis. Moreover, the soluble Aβ oligomers generated in this way
affect synapse function, decrease neuronal plasticity, alter energy and
glucose metabolism, induce oxidative stress and mitochondrial dys-
function, and disturb celular calcium homeostasis [2,5].
During the early 1990s, some genetic factors -apart from AβPP-
were shown to increase the risk of developing the disease, such as
apolipoprotein E (APOE) or presenilin 1 and 2 (PS1 and PS2) [7–11].
These factors were also involved in the amyloid cascade. For instance,
the allele for APOE ε4 was been shown to impair Aβ clearance and
promote its aggregation, leading to increased severity of this amyloid
pathology [7–12]. In spite of this, the existence of other factors that can
contribute to the pathogenesis of AD emphasizes its complexity. Some
of these risk factors are shown in Fig. 2.
Against this background, AD patients were classified into two
groups. The first one was formed for those subjects that developed the
pathology due to genetic causes leading to the production of classical
biomarkers like Aβ. This group covered about 3% of AD patients and
was dubbed “familial or early-onset AD”. The remaining 97% of pa-
tients were categorized as “sporadic or late-onset AD” (LOAD), whose
progression was associated with advanced age, hypertension, hyperli-
pidaemia, coronary disease, obesity and type 2 diabetes mellitus
(T2DM) [12–14].
T2DM is a complex disease with a chronic evolution that requires
continuous medical care, mainly focused on the reduction of global
cardiovascular risk, peripheral complications and cognitive loss [15].
Unlike type 1 diabetes mellitus (T1DM), an autoimmune disorder
characterized by the selective destruction of insulin-producing β-cells
[16,17], in T2DM there is an alteration in the mechanisms of uptake
and/or secretion of insulin. This leads to a chronic increase in blood
levels of glucose, resulting in a higher risk of macro and microvascular
complications. T2DM is also associated with insulin resistance (IR),
which is characterized by lower insulin activity at the cellular level, and
affects the metabolism of carbohydrates, lipids and proteins [15]. As we
have mentioned, in addition to a risk factor for cardiovascular pathol-
ogies, T2DM is also an independent risk factor for LOAD [11–14].
Specifically, it is widely recognized that T2DM and AD share several
kinds of abnormalities, including increased oxidative stress, impaired
glucose metabolism and insulin resistance characterized by continuous
hyperinsulinemia [12,12,13,14,18]. Likewise, some studies have
Fig. 1. Schematic representation of the APP’s protein processing in the cytoplasmic membrane. Both the amyloidogenic (right) and non-amyloidogenic (left)
pathways are depicted. The first one leads to the generation of Aβ oligomers that cause glial activation, mitochondrial alterations, synapse dysfunction as well as ER
stress and insulin resistance. The second one favours the generation of the sAβPPβ peptide, which has been described to have neuroprotective effects: it promotes
neurogenesis, favours insulin receptor activation and inhibits BACE1.
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focused on the role of insulin receptor (IR), which might be an im-
portant player in the pathology of AD, by contributing to the bio-
chemical, molecular and histopathological characteristics of the pa-
thology [13,19–27].
Given that the origin of the pathology is still unknown, and that
there seem to be many players involved in its development, AD has
been defined as a multifactorial disease (Fig. 2). Consequently, there
are different research areas, in addition to neuroscience, trying to elu-
cidate the origin of this pathology. In fact, prospective epidemiological
studies have identified metabolic syndrome and T2MD as risk factors
for multiple diseases of the nervous system [18–20]. Furthermore, an-
imal studies have shown that hypercaloric diets affect the structure and
functions of the hippocampus, although the specific mechanisms are
unclear [28,29]. Thus, it has been reported that AβPPswe/PS1dE9
(AβPP/PS1) transgenic mice fed with a diet enriched in palmitic acid,
showed reduced IR and increased insoluble Aβ peptide levels, as well as
cognitive deficits [30]. Moreover, Ho and colleagues found evidence
linking insulin resistance and increased relative risk for AD neuro-
pathology development, by demonstrating that IR signalling can in-
fluence Aβ production in the brain [31]. These results evidenced the
relationship between metabolic alterations and progression of AD fea-
tures, thus reinforcing the hypothesis of a metabolic aetiology of AD.
Indeed, it has been proposed to re-name AD as “type 3 diabetes mel-
litus” (T3DM) or brain-specific diabetes [32].
The present review is a state-of-the-art about the relation among
obesity, Aβ oligomers and the IR modulation. In addition, we discuss
the potential application of drugs modulating the brain insulin receptor
pathway as targets for AD prevention.
2. An historical overview of AD’s hypotheses and available
pharmacological treatments
Altghough over a century has passed since AD was first described,
the pathogenesis of this complex disease is still unclear. A number of
theories about AD origin have been postulated so far and several drugs
have been tested in accordance. The first one, proposed in the 80 s, was
the “cholinergic hypothesis”, which suggested that a dysfunction of
acetylcholine-containing neurons in the brain contributes substantially
to the cognitive decline observed in AD patients [33–35]. This para-
digm led to the development of the anticholinesterase inhibitors
(AChEI), which are currently in the market and provide a symptomatic
treatment of the disease [34–38]. However, these drugs only achieve a
temporary improvement and they do not slow down or cure AD.
In 1992, a series of discoveries opened the door to the birth of the
“amyloid cascade hypothesis”, which we have already discussed. This
hypothesis stressed the role of Aβ peptide deposition in AD pathogen-
esis, leading to neurofibrillary tangles, cell loss, vascular damage, and
dementia [39–42]. Ostensibly, the appearance of plaques and the onset
of AD would be related to the most common isoforms of Aβ, (1–40) and
(1–42) [40–43]. However, some current preclinical discoveries pointed
to Aβ as a cofactor or aggravator involved in a complex network of
pathological changes in the brain, instead of considering Aβ as the main
neurotoxin causing AD per se [44–48]. In any case, most drugs designed
to inhibit amyloid synthesis have failed to modify the evolution of the
disease. Notwithstanding, Verubescetat, a drug targeting Aβ or in-
hibiting the β-site amyloid precursor protein cleaving enzyme 1
(BACE1), was reported to be more effective than placebo in treating AD
[47,48].
Besides Aβ plaques, NFTs constitute the other main intracellular
hallmark of AD. It was demonstrated that NFTs were composed of tau
[48,49], a microtubule-associated protein (MAP) which acts as a major
regulator of microtubule formation [50–53]. Interestingly, it was ob-
served that the hyperphosphorylation of tau led to unconstructed mi-
crotubules and the appearance of helically crossed filaments that ag-
gregate to form the NFTs [50–53]. In some cases, the presence of NFTs
was correlated with the degree of dementia in patients with AD [53].
All these observations paved the way for the “tau hypothesis”, which
postulates that the origin of AD is associated with an early conforma-
tional change in the structure of tau [54]. Indeed, it has been demon-
strated that the reduction of hyperphosphorylated tau alleviates the
cognitive alterations induced by Aβ in a transgenic mice model of AD
[55]. Although in terms of research the tau hypothesis has been a
“supporting actor” when compared to the amyloid hypothesis, some
anti-tau therapies have shown promising results [48,51]. For instance,
TRx0237 (LMTX) is being currently tested in a phase III clinical trial as
an inhibitor of tau aggregation, capable of reducing tau-mediated
Fig. 2. Some risk factors for the development of sporadic AD. Age, APOE ε4 mutation, diet and lifestyle, gender, mental activity, cranioencephalic traumatisms and
others factors such as lack of social engagement have been associated to the onset and/or progression of AD.
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neuronal damage (clinical trial NT02245568). By this mechanism, this
drug could modify the course of AD [48]. On another front, it has been
reported that soluble oligomers of Aβ are able to accelerate the hy-
perphosphorylation of tau [4,50]. Nevertheless, although the two
markers are closely related neuropathologically, a mechanism linking
both theories is still missing.
Evidence showing inflammatory microglia consistently associated
with senile plaques in AD led to the “inflammation hypothesis” [56].
Indeed, it is known that local reactivity responses, such as microgliosis
and astrogliosis, could be involved in the development of AD by fos-
tering a severe neuroinflammation through the release of cytokines
[42,56–62]. However, while it is accepted that neuroinflammation
contributes actively to the development of AD, the fundamental ques-
tion remains: is it the cause or the consequence of the underlying pa-
thology? [60–64]. In this sense, the drug TTP488 (azeliragon), a re-
ceptor for advanced glycation end products (RAGE) antagonist with
anti-amyloid and anti-inflammatory properties is in a phase III trail. It
has been shown that this compound reduces amyloid uptake in brain
and lowers the inflammatory reaction in glial cells (NCT02080364)
[48].
Finally, another major hypothesis about AD is the “excitotoxic hy-
pothesis”, which describes how over-activation of glutamatergic
transmission, especially of N-Methyl-D-aspartate receptors (NMDARs),
leads to a massive influx of calcium (Ca2+) that damages neurons [65].
In mammals, NMDARs are distributed throughout the brain and mainly
in the hippocampus. The hyperactivation of these receptors leads to the
activation of a wide variety of intracellular pathways, inducing
homeostatic alterations and diminishing neuronal viability, eventually
leading to neuronal death [66–68]. However, the mechanism by which
this process is carried out remains unclear since, even though this hy-
pothesis advocates for an over-activation of NMDARs, it has been ob-
served that patients who developed AD actually had a reduction of the
number of these receptors in the cellular membrane [68]. Apparently,
the lack of receptors leads to an increase in their sensitivity, causing a
continuous activation leading to a progressive neurodegeneration due
to the excitotoxic damage [68–70]. Interestingly, this also seems to be
related to Aβ, since it has been demonstrated that Aβ causes an increase
of the endocytosis of the NMDARs in cortical neurons, hence decreasing
their expression in the membrane, which leads to an inhibition of sy-
naptic plasticity [70]. Regarding the excitotoxic hypothesis, meman-
tine, a NMDAR antagonist, was approved for the treatment of moder-
ately severe to severe AD in 2002 by the European Agency for the
Evaluation of Medical Products (EMEA). Unfortunately, as with any
other approved treatment for AD so far, mematine only have shown
symptomatic effects.
3. Mechanisms linking obesity and cognitive decline: results from
preclinical models
Nearly 20 years ago, the Rotterdam study reported that T2DM pa-
tients had increased risk to suffer dementia [71,72]. Today, obesity and
diabetes, two T2DM-related disorders, are well established risk factors
for AD [11,23,71–74]. In fact, it is of general concern that accumulation
of fat in the adipose tissue favours the emergence of metabolic syn-
drome and T2DM, due to IR signalling deficits in peripheral tissues.
What is, perhaps, not so widely known is that obesity also affects the
central nervous system (CNS) and it is associated with an exacerbation
of cognitive decline [75]. In this respect, data from the clinical study
Whitehall II and other research projects established a relation between
body mass index (BMI) values (> 30 kg/m2), aging (> 50 years old)
and the onset of cognitive deficits [73–78]. Nowadays, the molecular
mechanisms at fault are still being studied. For instance, many authors
suggest that vascular risk factors and inflammatory responses could also
have significant roles [79–82].
Since the pathogenesis of AD remains unclear, it is necessary to use
mixed models covering different hypothesis of the disease, evaluating
neuronal dysfunction, synapse loss and cell death, as well as po-
tentiating Aβ effects in order to better understand its role in these
neuropathological events [80–86]. For now, it seems that Aβ (1–42)
oligomers would have a synergistic effect, accelerating the mechanisms
related to cognitive impairment [86–89].
From a preclinical level, diet-induced obesity in in vivo models re-
presents a suitable and reproducible method for identifying and un-
derstanding potential mechanisms involved in T2DM or IR-induced
cognitive loss. Using this experimental approach, the research group of
Marta Di Carlo reported that rodents under a high fat diet (HFD) (60%
kcal from fat) during 7 months exhibited brain abnormalities similar to
the hallmarks of AD, such as the increase in tau phosphorylation,
neuroinflammation and memory loss [90]. In addition, they demon-
strated that those mice showed an increase in Aβ levels, which was
associated with an increase in AβPP and BACE1 expression, both ac-
companied by an increase in oxidative stress and mitochondrial dys-
function. Our research group also demonstrated that mice fed with a
HFD (45% kcal from fat) for 12 months, displayed insoluble Aβ peptide
depositions in the brain, thus confirming the relation between the triad
obesity, Aβ and cognitive loss [91].
Moreover, other studies showed that HFD-induced brain insulin
resistance could decrease synaptic vesicle recycling, thus diminishing
synaptic strength and leading to deleterious effects on cognitive beha-
viour [92]. In a preclinical study, Hao and co-workers demonstrated
that only three months of HFD feeding lead to a reversible deterioration
of hippocampal synaptic plasticity, dendritic spine density and spatial
memory in mice [93]. The authors propose that HFD activated a re-
versible microglial synaptic phagocytosis process. In this line of re-
search, Osborne and co-workers provided key findings on the implica-
tion of Aβ in memory loss in HFD fed rodents [94]. In this study, they
showed that intrahippocampal infusion of Aβ33–42 antibodies, with
preferential affinity for aggregated Aβ oligomers, improved the
memory process in rodents with HFD-induced cognitive loss. In addi-
tion, the authors identified a potential mechanism involved in the
process of cognitive impairment through the alteration of glutamate
transmission by dysregulation of hippocampal α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptors (AMPAR). However, other
authors reported a detrimental cognitive effect of obesogenic HFD in
3xTgAD mice that was not associated with an increase in the brain le-
vels of plaques, Aβ and tau [95]. Contrarily, Vandal and co-workers
reported that an obesogenic diet induced insulin resistance in both non-
transgenic and 3xTgAD mice, which worsened due to the HFD-amyloid
pathology exacerbation [96]. This suggests that HFD exerts a sy-
nergistic effect with AD-like pathology in 3xTgAD mice. Moreover, it
has been described that the noxious effects of Aβ in brain can also
contribute to pancreatic cell degeneration and insulin secretion, and,
conversely, abnormal systemic changes might not only develop sec-
ondary to brain dysfunction but might also affect AD progression [97].
This suggests that the interactions between the brain and the periphery
act as a vicious circle with a crucial role in the development and pro-
gression of AD [97]. These data are in line with other studies showing
that brain Aβ could bind to IR in the liver and favour peripheral insulin
resistance [98,99].
In another study, Ho and colleagues reported that HFD-induced
insulin resistance was associated with a decrease in neuronal IR sig-
nalling and insulin degrading enzyme (IDE) expression in Tg2576 mice,
thus promoting cognitive loss and increased Aβ plaque formation [31].
These results were confirmed by other researchers [100]. In this regard,
it is important to emphasize that IDE does not only degrade insulin, but
also Aβ [30]. Thus, a decrease in its brain levels may contribute to both
insulin signalling dysfunction and accumulation of Aβ. Likewise, other
studies using animal models of obesity revealed that HFD induced an
alteration in brain GLUT1 and GLUT3/GLUT4 glucose transporters,
decreasing its up-take into the CNS. This was linked to cognitive deficits
in the CA1 region of the hippocampus, which indicates an impaired
synaptic plasticity [101]. Moreover, Ruiz and co-workers added
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another interesting point by reporting that HFD increased peripheral
glucose levels in AβPP/PS1 mice, probably due to hypothalamic al-
terations [102]. Other studies provided data about the molecular me-
chanisms involved in obesity-mediated neurodegeneration. For in-
stance, previous results from our group reported an important down-
regulation of PPARγ-coactivator-1α (PGC-1α) in AβPP/PS1 transgenic
mice, a preclinical model of AD, under a HFD [30]. HFD caused a
dropdown of PGC-1α levels, which was mediated by a decrease of
phosphorylated cAMP response element-binding (p-CREB) protein le-
vels [30]. The importance of these results is highlighted by the fact that
PGC-1α has a key role in the mitochondrial biogenesis process and,
therefore, in the mitochondrial function, which is essential to neuronal
activity. Our study also demonstrated acceleration in the process of
memory loss in AβPP/PS1 transgenic mice under a hypercaloric diet, as
shown by short-term recognition memory values obtained in the novel
object recognition test (NORT). This memory impairment was probably
mediated by alterations in the brain IR and mitochondria [30]. Inter-
estingly, a correlation between the down-regulation of PGC-1α ex-
pression and AD has been also demonstrated, and the low expression of
PGC-1α in the brain of transgenic mice models of AD increases the
formation of Aβ through the increase in BACE1 activity across the
amyloidogenic route [103–107]. Accordingly, Katsouri and co-workers
reported that the stereotaxic administration of a lentiviral vector to
express human PGC-1α in the hippocampus and cortex of AβPP23
transgenic mice improved memory and showed neuroprotective effects,
hence demonstrating the efficacy of this gene therapy as a potential
treatment of AD [104]. In turn, Martins and co-workers reported that
HFD impairs memory in 3xTgAD mice. This cognitive alteration was
associated with changes in mitochondrial energetic balances and loss of
synaptic contacts [107]. Since synapses are sites of high-energy de-
mand, some authors correlate the synaptic degeneration process with
dysfunctional mitochondria, which are transported to synaptic term-
inals where high levels of ATP production are required [107].
In the same line, Sah and co-workers found that 3xTg mice fed with
HFD suffered from memory impairment associated with a significant
decrease in the expression of antioxidant enzymes, such as Heme oxy-
genase-1 (HO-1) and manganese-dependent superoxide dismutase
(MnSOD), through the inactivation of protein kinase B (AKT)- Nuclear
factor (erythroid-derived 2 (NRF2) signalling pathway [108]. There-
fore, obesity decreases antioxidant enzymes required for brain neuro-
protection.
On another front, results obtained by Lin et al. revealed that 5XFAD
mice fed with HFD exhibited cognitive impairment and hippocampal
oxidative stress. Cognitive impairment is also believed to occur due to
decreased levels of brain-derived neurotrophic factor (BDNF), which is
a central molecule in synaptic plasticity [109]. Furthermore, this study
demonstrated that brain alterations are independent of peripheral me-
tabolic alterations, since glucose tolerance was not impaired in the
transgenic mice. In turn, Thériault and co-workers showed that the HFD
induces deterioration on cognitive performance in AβPP/PS1 mice,
which was associated with a decrease in the enzymatic activity of
matrix metallopeptidase (MMP)-9 and a reduction of mRNA and protein
levels of BDNF in the brain [110]. These results reinforce the hypothesis
of a metabolic aetiology in the molecular basis of the development of
AD at the preclinical level [111]. In addition, others demonstrated a
down-regulation of hypothalamic BDNF protein levels in HFD-fed
transgenic mice compared with wild type HFD-fed mice [112].
In summary, all these preclinical studies showed the existence of an
initial memory impairment process associated to obesogenic diets,
which could be partially explained by increased levels of soluble Aβ and
the inhibition of long term potentiation (LTP) linked to synapse loss. In
addition, the down-regulation of BDNF levels mediated by PGC-1α,
together with mitochondrial dysfunction, contribute to the decrease of
synaptic connections, a marker that correlates with dementia in AD.
Overall, these and other studies suggest that some improvement could
be achieved through proper lifestyles, by avoiding metabolic alterations
and designing therapies targeting one or some of these biomarkers.
4. Are ceramides the bridge between peripheral type II diabetes
and neurodegeneration in Alzheimer’s disease?
As discussed above, preclinical studies demonstrated that HFDs
enhance cognitive loss, stressing its central effects. However, HFDs can
also favour cognitive loss through peripheral alterations, specifically in
the liver and adipose tissue. In an interesting study, Lyn-Cook and co-
workers reported that HFDs induce liver damage (non-alcoholic stea-
tohepatitis), by increasing the levels of pro-inflammatory cytokines
(mainly TNFα) and ceramides [113]. Ceramides are toxic lipids which
play key roles in brain oxidative stress, insulin resistance and cytos-
keletal alterations, mechanisms involved in LOAD apparition [113]. In
this respect, Dr. De la Monte suggested that chronic obesity induces
insulin resistance associated with non-alcoholic steatohepatitis (NASH)
[11–14, 113]. In addition, T2DM-related obesity increases hepatic in-
sulin resistance, thus favouring inflammation and metabolic dysfunc-
tion, which leads to dysregulated lipolysis and the generation of cer-
amides [113]. A significant increase in ceramide levels promotes ER
stress in the liver, which exacerbates insulin resistance, inflammation,
and oxidative stress [11–13].
In addition to these peripheral harmful effects, ceramides originated
in adipose tissue or in the liver reach the bloodstream and pass through
the blood-brain barrier, exerting toxic effects in neurons [13]. In this
respect, we hypothesize that ceramides in association with Aβ 1–42
could exacerbate brain insulin resistance, oxidative stress, mitochon-
drial alterations and neuroinflamation. Thus, there could be a vicious
circle between brain and peripheral tissues: peripheral damage would
increase the risk of cognitive loss and the neurotoxic effects of Aβ 1–42
in the hypothalamus would lead to an altered regulation of peripheral
metabolism [114–116]. This idea is supported by the fact that Aβ 1–42
binds directly to the insulin receptor both in the periphery and in the
hypothalamus, inducing a peripheral glucose intolerance and insulin
resistance and eventually leading to T2DM [116]. Furthermore, it has
been demonstrated that Aβ 1–42 induces hepatic insulin resistance
through the activation of the Janus Kinase 2 (JAK2) in a preclinical
model of familial AD [99]. In addition to the liver, some authors have
shown that amyloid can accumulate in other peripheral tissues such as
pancreas and skeletal muscle [117,118]. Therefore, the Aβ 1–42 pep-
tide originated at the brain may constitute a key factor involved in
insulin resistance and T2DM [97].
Likewise, Shinohara and Sato proposed the involvement of an X
Factor underlying the bidirectional interactions between diabetes and
LOAD. Hence, they suggest the existence of a vicious circle between
diabetes and LOAD, which could be initiated by peripheral ceramides
[119]. According to this idea, the authors put forward a potential
equation where Aβ1–42 levels would be multiplied by an X factor. This
unknown factor could be ceramides, which may amplify the neuro-
toxicity of Aβ1–42 peptide. Consequently, cognitive loss could be pre-
vented by breaking this circle, and antidiabetic treatments could be
beneficial against LOAD.
5. Endoplasmic reticulum (ER) stress: a link between obesity and
cognitive loss
Some research studies have indicated that the ER stress is involved
in the appearance of degenerative diseases in the brain [120,121].
Obesity seems to exacerbate this situation, favouring cognitive loss and
promoting AD-like neuropathology [122–125]. As we have discussed
above, the accumulation of disease-specific misfolded proteins is a
hallmark of AD, and ER could have a key role in this process.
In eukaryotic cells, such as neurons, the ER is a cellular compart-
ment involved in calcium homeostasis, lipid biosynthesis and protein
folding and maturation. Under normal physiological conditions, ER
activity is paramount for most cellular mechanisms. Glucose-regulated
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protein 78 or binding immunoglobulin protein (GRP78/BiP) molecules
are bound to three different ER transmembrane receptor proteins,
known as the PKR-like endoplasmic reticulum kinase (PERK), inositol
requiring enzyme 1 (IRE1α) and activating transcription factor 6
(ATF6) [122]. Under ER stress, there is a release of BiP, which triggers
the activation of ER stress response. The activation of PERK pathway
leads to a signalling cascade which begins with the phosphorylation of
the eukaryotic initiation factor 2 alpha (eIF2α) and eventually attenu-
ates global protein synthesis [125]. Subsequently, this signalling
pathway also promotes the activation of several downstream proteins
like the activating transcription factor 4 (ATF4), proapoptotic C/EBP
homologous protein (CHOP) and growth arrest and DNA damage-in-
ducible protein 34 KDa (GADD34) [121,122].
In neurons, an appropriate ER response is necessary for the control
of protein synthesis and synaptic and neuronal function [125–127]. In
AD, alterations in this response could lead to defects to long-term
memory formation. Specifically, disruptions on the homeostasis of
protein folding lead to the accumulation of misfolded proteins in the ER
and upregulation of proapoptotic proteins like CHOP [124]. Hence,
conditions inducing a sustained brain ER stress and leading to activa-
tion of the unfolded protein response (UPR), such as obesity, could
clearly result in deleterious effects, although the underlying mechan-
isms are still not well understood. Some research groups have reported
that palmitate could be one of the elements responsible for the acti-
vation of these mechanisms in mice under HFD [128]. Thus, it was
hypothesised that the association of palmitate and Aβ could increase
even further the burden on the ER (Fig. 3) [129,130].
Other previous studies have shown that phosphorylation of eIF2α is
increased in the hipocampus of preclinical mice models of AD. For in-
stance, O’Connor and coworkers reported that PERK-eIF2α signalling
activation increases AβPP processing and Aβ formation via direct up-
regulation of BACE-1 [126]. This data was replicated in the 5xFAD mice
model by other groups, which also combined heterogeneous knockouts
for PERK+/− and the 5xFAD transgenic model (PERK haploinsuffi-
ciency) [131–133]. The results showed improvements in memory def-
icits in PERK+/− mice compared with 5xFAD mice. Furthermore, under
insulin-deficiency conditions, PERK-eIF2α ER stress signalling pathway
is dramatically activated in the brain of 5XFAD mice, thus increasing
AD risk [133]. Likewise, the PERK pathway effector ATF4 is a repressor
of CREB [121], which is required for synaptic plasticity as well as for
learning processes.
Complementarity, eIF2α could also be phosphorylated by three
different kinases associated with stressors. These kinases are the RNA-
activated protein kinase (PKR), the heme-regulated inhibitor kinase
(HRI) and the general control non-depressible 2 kinase (GCN2)
[87,88,134]. They belong to the integrated stress response (ISR) and
some of them have been linked to synapse loss and cognitive deficits in
human and preclinical mice models of AD. For example, Mouton-Liger
et al. reported that in human AD brains there is significant correlation
between increase in PKR and BACE1 protein levels [135]. Strangely,
Hwang and co-workers reported that PKR inhibition improves memory
without affecting Aβ load in the hippocampus in 12-month-old 5xFAD
mice [130]. The authors concluded that this PKR inhibition without
affecting Aβ levels might provide a promising alternative strategy for
developing a potential AD treatment. In another study, Ma and co-
workers crossed PERK and GCN2 knockouts with AβPP/PS1 transgenic
mice. They observed that eliminating either enzyme reduced brain le-
vels of Aβ and prevented memory deficits associated with the AβPP/
PS1 phenotype [136].
On another research line, Sims-Robinson and co-workers evidenced
an increase of ER stress activation on the hippocampus of B6-HF mice
fed with HFD. They concluded that this was due to an inhibition of the
IR signalling, probably mediated through the activation of the c-Jun N-
terminal kinases (JNKs), which are direct inhibitors of the IR substrate
1 (IRS1) [137]. Indeed, an increase in the phosphorylation rates of
serine amino acids of the IRS1 would induce desensitization of the
hippocampal IR and it is believed that the JNK1 isoform plays a pro-
minent role in this mechanism [138]. In the same line, Liang and co-
workers demonstrated a significant increase in the phosphorylation of
both PERK and eIF2α, as well as IRE1α and JNK, in hippocampus and
frontal cortex of HFD rats [139]. Therefore, they concluded that UPR
activation was increased in the brain of obese rats, and that this me-
chanism was involved in insulin resistance and cognitive loss through
JNKs activation and IRS1 inhibitory phosphorylation. This data sup-
ports the metabolic hypothesis of the appearance of cognitive deficits
independent of Aβ production.
The administration of ursolic acid is a potential strategy to find a
therapeutic approach for these alterations. This natural triterpenoid
compound exerts many pharmacological actions such as anti-oxidant,
anti-inflammatory and anti-tumoral effects. Thus, Lu and co-workers
demonstrated that ursolic acid has a protective effect preventing ER
activation in the hippocampus, hence improving cognitive responsive-
ness [128]. Furthermore, quercetin, a polyphenolic flavonoid com-
pound present in a variety of fruits and vegetables, exerts beneficial
effects on obesity and cognitive processes by preventing the activation
of PERK-eIF2α signalling pathway and avoiding phosphorylation of
ATF4 through GADD34 induction [140,141]. Likewise, it has been
shown that the administration of the polyunsaturated fatty acid α-li-
nolenic acid to aged female Sprague-Dawley rats fed with a HFD im-
proved the cognitive process [142]. Its beneficial effects are mediated
by the inhibition of UPR response through the down-regulation of brain
ATF4 levels, thus leading to the increase of p-CREB phosphorylation
rates [142].
6. Synaptic loss mediated by neuroinflammation in obesity
Obesity has been associated with chronic inflammatory processes
derived from the activity of hypertrophic adipocytes, free fatty acids
and reactive oxygen species [143–145]. In the CNS, microglia have
significant roles in the control of these mechanisms.
Under physiological conditions, microglial cells present a branched
morphology and are responsible for the production of anti-in-
flammatory and neurotrophic factors (inactive or unreactive state (M2)
[146]. However, in some conditions such as obesity, microglial cells
become reactive and change their morphology to amoeboid. This is
followed by an enhancement of pro-inflammatory responses, both on
microglia itself and in other cells such as astrocytes, through the release
Fig. 3. Chain of events relating obesity alterations, the accumulation of Aβ1–42
and the stress on the reticulum. Activating stimuli on the ER cause release of
BiP and the initiation of UPR signalling. These mechanisms have been related to
the appearance of pathologies like AD through the upregulation of apoptotic
and glial reactivity biomarkers.
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of certain cytokines (M1 state) [147]. Eventually, M1 microglia and
astrocytic activity lead to neuronal death and pathologies like AD
[148,149]. These assumptions have been supported by a meta-analysis
of cytokines, which revealed increased concentrations of interleukin 6
(IL-6) and tumor necrosis factor α (TNFα) in peripheral blood of AD
patients [150].
As discussed above, when any of the pathways of the UPR activates,
there is an up-regulation of nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-kB), a key modulator of pro-inflammatory genes
[151]. Likewise, several studies indicate that inflammation and ab-
normal ER activity are critical events in the establishment of hy-
pothalamic and peripheral insulin resistance in metabolic disorders.
Thus, in animal models of T2DM and obesity, inflammation in the hy-
pothalamus is an important part of the underlying pathogenic me-
chanism, especially the activation of TNF-α and the kinase inhibitor of
nuclear factor kappa-B kinase subunit beta (IKKβ)/NF-kB signalling axis
[87,88,116,152]. Specifically, under a HFD, IKKβ becomes activated
and phosphorylates IRS1 inhibitory serine sites, resulting in a desensi-
tization of IR signalling [57]. In addition, cortical and hippocampal
dysfunction seems to share common pathways in AD.
JNKs constitute another important element regulating inflammation
and IR. JNKs pathways control several processes, including insulin re-
sistance in peripheral tissues, such as liver or pancreas, and also in the
brain [153–155]. Usually, these pathways are upregulated by cytokines
and ER stress. Hence, it is known that neuroinflammation increases
brain levels of TNFα, which activates JNKs -mainly JNK1- and leads to
a decline of insulin signalling [56,57]. In addition, the activation of ER/
UPR response, specifically IRE1α pathway, triggers the splicing of X-
box binding protein 1 (XBP1) mRNA. The products of this splicing also
activate JNK. This process has important effects on the development of
apoptotic processes accounting for cognitive decline [156]. Ad-
ditionally, IRE1α can also be phosphorylated by JNKs, leading to a
recruitment of tumour necrosis factor receptor associated factor-2
(TRAF2), which would enhance further apoptotic responses through
caspase 12. Therefore, it seems that the UPR and JNKs are both in-
volved in neuronal apoptosis processes, which are favoured by obesity
[125,152].
Interestingly, the expression of protein-tyrosine phosphatase 1B
(PTP1B) also becomes up-regulated in obesity models using HFD [157].
This phosphatase is located in the ER membrane and it is a major ne-
gative regulator of insulin, leptin and BDNF receptors (Tyrosine Re-
ceptor Kinase B; TRKB). Under physiologic conditions, the upregulation
of PTP1B is promoted by TNFα and it has significant effects on cogni-
tion and memory formation. Elevated levels of PTP1B dephosphorylate
tyrosine residues and inhibit downstream signal transduction of the
previously mentioned receptors, but activate microglia [158]. In addi-
tion, it has been demonstrated that PTP1B is a regulator of the UPR
response through the modulation of PERK/eIF1α signalling in periph-
eral and neuronal cell culture studies [157]. Likewise, PTP1B inhibition
attenuates neuronal toxicity in the ER mediated by the mitochondrial
neurotoxin rotenone and tunicamycin [159].
Finally, soluble Aβ peptide oligomers can activate microglial cells
and increase TNF-α brain levels [56,57]. Therefore, obesity and Aβ can
together overstimulate an aberrant TNFα signalling, leading to activa-
tion of the stress kinases that block insulin signalling in the brain.
Following this line of thought, obesity and neurodegeneration may run
in parallel in a complex mechanism where the activation of NF-kB
would lead to the expression of inflammatory cytokines, hence pro-
moting a neuroinflammatory state.
7. Pharmacological approaches for metabolic late onset
Alzheimer’s disease treatment
According to the metabolic hypothesis of AD, therapies capable of
restoring normal brain insulin signalling in the CNS may have bene-
ficial effects on brain function. In this sense, a growing body of evidence
suggest that insulin receptor have multiple brain functions related to
cognition, neuroprotection through the activation of Akt, modulation of
AβPP and Aβ levels, neuroinflammation and synapsis formation. Hence,
brain insulin dysregulation could contribute to AD pathogenesis, and
drugs involved in the modulation of insulin receptor could have po-
tential application in the treatment of AD. This could be achieved not
only by improving brain cognition at the hippocampal level, but also
modulating the hypothalamus and peripheral tissues such as the liver,
which would improve metabolic diseases such as T2DM. Consequently,
bearing in mind that AD can be considered a metabolic alteration, its
treatment should not only focus in brain processes such as memory, but
also in peripheral organs related to insulin resistance (Table 1).
7.1. Intranasal insulin
Mao and co-workers reported that the administration of intranasal
insulin for 6 weeks in AβPP/PS1 mice improves cognitive function by
activating non-amyloidogenic pathways that favour a decrease in brain
Aβ levels and Aβ plaque deposits [160]. Therefore, activation of brain
insulin receptors improves Aβ pathology at preclinical level and in-
tranasal insulin may be a potential strategy to modify the course of AD
(Table 1).
Several clinical studies have also examined the effects of intranasal-
administered insulin in AD patients. For instance, Craft and co-workers
Table 1
Clinical trials that are being conducted with drugs that act by activating the insulin receptor and the signaling pathway for the treatment of Alzheimer’s disease.
Drug Phase CT number Disease
Rosiglitazone II NCT00381238 Mild to moderate AD
Rosiglitazone II NCT00334568 Examine the drug response in patients with AD
Rosiglitazone I NCT00688207 AD (the study is designed to assess the pharmacokinetics of Rosiglitazone)
Rosiglitazone III NCT00428090 Mild To Moderate AD
Rosiglitazone III NCT00550420 Mild to moderate AD
Rosiglitazone III NCT00348309 Mild to moderate AD
Pioglitazone II NCT00982202 AD
Pioglitazone III NCT01931566 Mild to moderate AD
Pioglitazone III NCT02284906 AD
Intranasal Insulin Glulisine II NCT01436045 Mild To Moderate AD
Intranasal insulin detemir II NCT01595646 AD or amnestic mild cognitive impairment
Metformin II NCT00620191 Amnestic Mild Cognitive Impairment
Liraglutide Not Applicable NCT01469351 AD
Exendin-4 II NCT01255163 AD
Exendin-4 III NCT02847403 Cognitive Decline in Dysglycemic Patients
HM15211 I NCT03374241 Obesity
GIP/GLP-1 Co-Activity Not Applicable NCT03526289 Overweight and Type 2 Diabetes
Insulin NCT00438568 Mild To Moderate AD
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evaluated the effects of intranasal administrations of either insulin (10
or 20 IU twice a day for a total dose of 20 or 40 IU per day) or placebo
(saline twice a day) for 4 months in AD patients (clinical trial number
NCT00438568) [161,162]. They assessed changes in cognitive para-
meters, brain glucose metabolism and Aβ levels in cerebrospinal fluid
(CSF). The results of the trial suggested that the administration of in-
tranasal insulin could improve cognition and brain glucose metabolism
in patients with mild cognitive impairment or AD.
After the potential positive effects of intranasal insulin in AD, dif-
ferent pharmaceutical preparations of insulin have been developed to
improve its bioavailability. For example, insulin detemir incorporates
fatty acids to its chemical structure, thus increasing its binding to al-
bumin and allowing a slower elimination, which lengthens its half-life
[162]. Craft and co-workers reported that the positive effects of insulin
detemir on memory are associated with an increased volume in brain
regions affected by AD neuropathology [162]. However, the authors
reported that the efficacy of insulin detemir decreased over longer-term
administration in these patients, whereas regular insulin continued to
provide beneficial effects on memory. The explanation of these results
is still unclear, although it has been proposed that long-acting insulins
may desensitize the insulin receptor and thereby increase insulin re-
sistance [56].
Finally, is worth to mention that cognitive processes in AD patients
are influenced by gender and APOE4. Interestingly, cognition function
in APOE4-negative patients is usually improved after intranasal insulin,
while APOE4-positive AD patients showed contradictory results
[26,163]. Likewise, men respond better to insulin than women [26].
7.2. Incretins
This group includes some synthetic long-acting analogs such as
Glucagon-like peptide-1 (GLP-1), receptor agonists such as exendin-4,
as well as liraglutide and lixisenatide, which possess insulinotropic
activity, among others.
At preclinical level, intraperitoneally administration of liraglutide
or lixisenatide improves neuropathological markers of AD, such as de-
crease in the number of plaques and glial activation, and also improves
cognition parameters in AβPPSwe/PS1dE9 mice [164]. However, sev-
eral clinical studies are now evaluating the potential efficacy and safety
of GLP-1 mimetics in AD, such as liraglutide. For instance, the clinical
trial NCT01469351 evaluated the efficacy of liraglutide in AD patients,
reporting that 6-month treatment with this drug improved brain glu-
cose metabolism with a slight improvement on cognition (Table 1).
Another clinical study, the NCT02140983, evaluated the effects of lir-
aglutide on memory and attention of elder patients with insulin re-
sistance. Worth to mention, the patients had pre-diabetes and half of all
subjects had a family history of dementia. However, no data from this
study has been reported yet. Exendin-4 is another incretin-mimetic
long-acting GLP-1 receptor agonist approved for T2DM treatment,
which also have shown neuroprotective effects in preclinical models of
AD [165]. Unfortunately, clinical trials with exendin-4 in early-stage
AD, such as NCT01255163, did not reported beneficial effects on cog-
nition.
Likewise, glucose-dependent insulinotropic polypeptide (GIP) ana-
logues such as D-Ala2-GIP also showed neuroprotective effects on sy-
naptic plasticity and cognition in animal models. Thus, it has been re-
ported that these compound significantly reduces Aβ42 plaques and
neuroinflammation in preclinical AD mice models [166]. Since these
peptides were effective at the preclinical level, the next strategy was the
development of dual peptide agonists GLP-1/glucagon and GLP-1/GIP
combined. Moreover, triagonists GLP-1/GCG/GIP are in early stages of
development. Thus far, two studies in murine AD models have reported
that triple agonists improve cognitive processes by increasing BDNF
levels and p-CREB signalling pathway, and by decreasing plaques and
neuroinflammation [167]. However, most research studies with tria-
gonists have been carried out in metabolic disorders such as T2DM and
obesity, where they are more effective than the single administration of
each peptide alone. Regarding clinical studies, only the triagonist
HM15211 is under investigation as a treatment for obesity
(NCT03374241). In this sense, the next aim is to evaluate the efficacy of
this triagonist, which integrates the actions of the three endogenous
hormones, in T2DM and weight decrease, as well as in other potential
diseases.
7.3. Metformin
It has been shown that the anti-diabetic drug metformin is effective
in preclinical models of AD [168]. Thus, Ou and co-workers reported
that metformin improves cognitive process, decrease the Aβ production
and neuroinflammatory response in the hippocampus of AβPP/PS1
mice [169]. The authors suggested that the neuroprotective effects of
metformin are mediated by the modulation of the AMPK/mTOR/S6K/
BACE1 pathway. However, these neuroprotective benefits of metformin
in AD are contradictory, since a recent study in transgenic models of
tauopathy with cognitive deficits has shown that metformin can ag-
gravate the risk of tauopathy in diabetic patients [170].
In turn, Infante-Garcia and co-workers studied in a mixed murine
model of AD and T2DM (AβPP/PS1x db/db mice) the effects of the anti-
T2DM polypill (PP), which contains several drugs used to treat T2DM,
including metformin, aspirin, a generic statin, and an angiotensin-
converting enzyme inhibitor [171]. They reported that PP could be a
suitable strategy for the treatment of serious complications of T2DM,
such as cognitive alterations.
Recently, Koenig and co-workers published the results of a clinical
trial with metformin (NCT01965756) in AD patients with mild cogni-
tive impairment or mild dementia. They reported that metformin
slightly improved learning and memory processes [172]. In another
clinical trial (NCT00620191), the effects of metformin in Amnestic Mild
Cognitive Impairment (MCI) were evaluated. Specifically, the aim of
this study was to assess the changes in a memory and general cognitive
function test (the Alzheimer’s Disease Assessment Scale-cognitive sub-
scale-ADAS-Cog used in clinical trials.). The study also aimed to com-
pare brain function through mean changes in PET scan between the
patients treated with metformin and those treated with placebo. So far,
no results from this study have been reported yet.
7.4. Thiazolidinediones
Thiazolidinediones are agonists of peroxisome-proliferator activated
receptors (PPARs). They possess antidiabetic activity and have also
shown neuroprotective effects in preclinical models of AD [48]. These
compounds are nuclear hormone receptors that induce physiological
responses through the regulation of gene expression, and they are in-
volved in the metabolic regulation of carbohydrates, proteins and li-
pids. They also reduce neuroinflammation by inhibiting glial activation,
since it has been reported that rosiglitazone significantly improves
cognition in rats after Aβ injection in the hippocampus through in-
hibition of microglial cytokine release [173]. According to these results,
the regulation of microglia constitutes a key target involved in cogni-
tive improvement in preclinical AD models.
Regarding the use of rosiglitazone in clinical studies, Gold and
colleagues reported that administration of 2-mg or 8-mg of this com-
pound during 24 weeks in APOE-ε4 negative patients does not show any
statistical difference when compared to placebo treatment [174]. The
current clinical study NCT00334568 aims to evaluate the effects of
rosiglitazone on i) cerebral glucose utilization measured by [18F] FDG
uptake and ii) cognitive process in AD. No results have been reported
yet. In turn, the study NCT00348309 assessed the effects of a 54-week
treatment of rosiglitazone (extended release tablets) combined with
donepezil on cognitive parameters of patients with mild to moderate
AD. Again, no clinical improvement was achieved with this treatment
[175].
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On another front, previous studies have reported neuroprotective
effects of pioglitazone in preclinical models of AD, through a decrease
in neuroinflammation and also in mRNA and protein levesl of BACE1
[176]. This compound was able to significantly decrease the cerebral
Aβ levels, and could hence constitute a potential drug with the capacity
to modify the course of the disease. Interestingly, Fernandez-Martos
and co-workers reported that acute 2-week treatment with combined
leptin and pioglitazone improves cognition and decrease neuropatho-
logical parameters of AD in AβPP/PS1 mice [177]. In turn, Geldmacher
and colleagues evaluated the safety of long-term treatment with pio-
glitazone (15-mg tablets) in elderly nondiabetic AD patients [178]. The
authors reported that pioglitazone was well tolerated and safe during
the 18-month treatment trial. In the same line, the NCT01931566 study
evaluated the effects of pioglitazone compared with placebo in AD
patients with mild cognitive impairment (MCI). The aim of this study
was to delay the onset of memory loss in cognitively normal partici-
pants who were at high-risk for developing MCI within the next 5 years.
Currently, no results have been reported. However, the clinical trial
NCT02284906 aims to evaluate the safety and effectiveness of piogli-
tazone on cognitive function in participants who have completed the
previous study.
Regarding thiazolidinediones, we can summarize that, in spite the
promising results observed in preclinical studies, no clinical study has
reported successful results yet [179–181]. Therefore, additional clinical
studies with PPARγ agonists are still required, either in monotherapy or
in combination with other drugs, in order to evaluate the efficacy in
improving brain insulin/IGF-1 resistance and thus improving cognition
and preventing neurodegeneration in initial stages of AD.
7.5. c-Jun-N-terminal kinase inhibitors
Although SP600125 is the best characterized inhibitor of JNK ac-
tivity, its application has been impeded by its low target selectivity, and
the clinical efficacy of this compound is also limited by its poor aqueous
solubility [157].
Chalcones are phenolic naturally compounds highly widespread in
fruits, vegetables, spices, tea and soy-based foodstuff. Some of these
compounds have been shown to inhibit JNK pathway and they are
considered important secondary metabolites, precursors of flavonoids
and isoflavonoids in plants [182]. Moreover, these molecules are in-
teresting due to their simple chemistry, easy synthetic procedures,
multiplicity of substitutions and diverse pharmacological potentials,
such as anti-cancer, antioxidants, anti-inflammatory, adenosine re-
ceptor ligands, antimalarial, antimicrobial, anti-HIV or anti-protozoal
[183–187]. Over the years, different chalcones have been isolated, such
as isoliquiritigenin, echinatin, licochalcone A (Lic-A), licochalcone C
and licochalcone E (Lic-E).
Lic-E exhibits cytotoxicity to human tumor cell lines and endothelial
cells, as well as cutaneous anti-inflammatory potential [186]. More-
over, Lic-E activates the NRF2-Antioxidant Response Element (ARE)
system and up-regulates downstream NAD (P) H: quinone oxidor-
eductase 1 (NQO1) and HO-1, suggesting a therapeutically relevant
effect to oxidative-stress-related neurodegeneration [182]. In addition,
it has been evidenced that Lic-E has a neuroprotective effect against 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which induces
nigrostriatal dopaminergic neurodegeneration in mice [186].
Lic-A could be a promising molecule for the treatment of obesity-
derived complications associated with cognitive impairment. It is one of
the major bioactive constituents of the roots of liquorice and it has been
shown to have anti-inflammatory and anti-microbial activities, as well
as anti-tumour effects [187,188]. Lic-A is a specific inhibitor of JNK1
and studies using JNK1 knockout mice revealed that these animals
showed lower body weight and increased insulin sensitivity [(Busquets
et al. 2018). Moreover, Lic-A has been identified as a PTP1B inhibitor,
hence increasing its potential effect for the treatment of T2DM at per-
ipheral level and enhancing the cognitive process in the brain. Of note,
our group has reported beneficial effects of this molecule in a murine
model of epilepsy [135,184,185], by demontsrating that JNK1 inhibi-
tion by Lic-A reduced cell death derived of excitotoxic damage, as well
as neuroinflammation.
Additionally, several research studies have synthesized and eval-
uated hydroxychalcones as inhibitors of human acetylcholinesterase.
These new compounds were found to be effective and could be poten-
tial new disease-modifying drug candidates for the treatment of AD.
Thus, Jeon and co-workers synthesized hydroxychalcones with potent
BACE1 inhibiting effect, preventing the formation of insoluble Aβ
Fig. 4. Graphical representation of some of the mechanisms described. JNKs are mediators of proliferative, inflammatory and apoptotic mechanisms. Lic-A, a
chalcone extracted of liquorice roots, behaves as a specific inhibitor of the JNK1.
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peptide, as well as inhibition of MAPK signalling and TAU phosphor-
ylation [186,187]. In addition, novel selective water-soluble and brain-
penetrant JNK inhibitors have been tested [188]. Likewise, some ex-
periments have evaluated the effects of i.p. and i.c.v. administrations of
SR11935 and SR3306, brain-penetrant JNK2/3 isoform-selective in-
hibitors [188]. The results showed similar anorectic effects for both
isoforms, suggesting that JNK2 and JNK3 mediate aspects of the an-
orectic effect observed in pan-JNK inhibition.
8. Concluding remarks
It has been described that obesity enhances the loss of neurons
[189]. Therefore, it is paramount to investigate how this condition is
associated with soluble Aβ and how it promotes age-related pathologies
[190,191]. Ceramides are generated in peripheral tissues during the
obesogenic process. In the brain, these toxic lipids could amplify and
potentiate the neurotoxic effects of Aβ1–42 [192]. Hence, drugs with
antidiabetic peripheral effects are expected to be capable of preventing
the cognitive loss in LOAD, by inhibiting the enhancing effects of cer-
amides on Aβ1–42 [193–199].
In addition to obesity and altered insulin receptor activity, there is
mounting data pointing to ER strees and neuroinflammation as key
mechanisms in sporadic AD development [200]. Indeed, obesity causes
ER stress by promoting a pro-inflammatory state through the activation
of molecules like PTP1B and JNK, as well as by increasing Aβ levels
through BACE1 activation in the amyloidogenic pathway [201,202].
Moreover, PTP1B and JNK are also relevant in the regulation of IR
signalling, pleading to its inhibition and the appearance of insulin re-
sistance. In this sense, JNKs emerge as molecular targets that could
restore homeostasis alterations related to insulin resistance, ER stress
and neuroinflammation [203–205]. In order to modulate these me-
chanisms, different pharmacological approaches that may act in a
combined and, potentially, synergistic manner have been proposed.
Efforts should be addressed to achieve a better understanding of the
precise role of each JNK isoforms in brain and during cognitive im-
pairment, as well as to test effective and specific pharmacological in-
hibitors.
Finally, drugs modulating one or several of these mechanisms could
be a pharmacological strategy to prevent AD. Licochalcones are po-
tential candidates, since these compounds have shown different neu-
roprotective properties. Specially, Lic-A is a promising compound due
to its inhibitory activity on JNK1 and PTP1B [203–205]. Thus, Lic-A is
capable of reducing neuroinflammation and insulin resistance, two of
the pathological hallmarks of sporadic cognitive loss related to AD
(Fig. 4). Likewise, preclinical studies and clinical trials indicate that the
intranasal administration of insulin, the administration of incretins and
other antidiabetic drugs can also have a therapeutic application in the
prevention of AD [206–214]. However, as to other diseases such as
AIDS or the prevention of coronary heart disease, a combined treatment
could be necessary for the successful treatment of AD.
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